1767 / 1851
Endpoint
STAR-01
ACCORD
12/0405
CAO/ARO/
AIO-04
NSABP
R-04
PETACC-6 FOWARC
PCR
16%
both
arms
14%
vs
19%
12.8%
vs
16.5%
(p=0.038)
19% vs
21%
11.5%
vs
13%
14%
vs
27.5%
CRM
4%
vs 7%
8%
vs 13%
5%
vs 6% No data
2%
vs 2%
9.2%
vs
10%
R1/R2
yp Node +
(stage III)
29%
vs
26%
30%
vs
26%
27%
vs 26% Not
stated
27%
vs
26%
19.9%
vs
12.6%
Oxaliplatin Phase III trials:
Control arm in red